Biró E, Sturk-Maquelin K N, Vogel G M T, Meuleman D G, Smit M J, Hack C E, Sturk A, Nieuwland R
Department of Clinical Chemistry, Academic Medical Center, University of Amsterdam, The Netherlands.
J Thromb Haemost. 2003 Dec;1(12):2561-8. doi: 10.1046/j.1538-7836.2003.00456.x.
Circulating microparticles of various cell types are present in healthy individuals and, in varying numbers and antigenic composition, in various disease states. To what extent these microparticles contribute to coagulation in vivo is unknown.
To examine the in vivo thrombogenicity of human microparticles.
Microparticles were isolated from pericardial blood of cardiac surgery patients and venous blood of healthy individuals. Their numbers, cellular source, and tissue factor (TF) exposure were determined using flow cytometry. Their in vitro procoagulant properties were studied in a fibrin generation test, and their in vivo thrombogenicity in a rat model.
The total number of microparticles did not differ between pericardial samples and samples from healthy individuals (P = 0.786). In both groups, microparticles from platelets, erythrocytes, and granulocytes exposed TF. Microparticle-exposed TF antigen levels were higher in pericardial compared with healthy individual samples (P = 0.036). Pericardial microparticles were strongly procoagulant in vitro and highly thrombogenic in a venous stasis thrombosis model in rats, whereas microparticles from healthy individuals were not [thrombus weights 24.8 (12.2-41.3) mg vs. 0 (0-24.3) mg median and range; P < 0.001]. Preincubation of pericardial microparticles with an inhibitory antibody against human TF abolished their thrombogenicity [0 (0-4.4) mg; P < 0.01], while a control antibody had no effect [19.6 (12.6-53.7) mg; P > 0.05]. The thrombogenicity of the microparticles correlated strongly with their TF exposure (r = 0.9524, P = 0.001).
Human cell-derived microparticles promote thrombus formation in vivo in a TF-dependent manner. They might be the direct cause of an increased thromboembolic tendency in various patient groups.
各种细胞类型的循环微颗粒存在于健康个体中,并且在各种疾病状态下数量和抗原组成各不相同。这些微颗粒在体内对凝血的贡献程度尚不清楚。
研究人微颗粒的体内血栓形成能力。
从心脏手术患者的心包血和健康个体的静脉血中分离微颗粒。使用流式细胞术确定其数量、细胞来源和组织因子(TF)暴露情况。在纤维蛋白生成试验中研究其体外促凝特性,并在大鼠模型中研究其体内血栓形成能力。
心包样本和健康个体样本中的微颗粒总数无差异(P = 0.786)。在两组中,来自血小板、红细胞和粒细胞的微颗粒均暴露TF。心包微颗粒暴露的TF抗原水平高于健康个体样本(P = 0.036)。心包微颗粒在体外具有很强的促凝作用,在大鼠静脉淤滞血栓形成模型中具有高度血栓形成能力,而健康个体的微颗粒则没有[血栓重量中位数和范围分别为24.8(12.2 - 41.3)mg与0(0 - 24.3)mg;P < 0.001]。用抗人TF抑制性抗体预孵育心包微颗粒可消除其血栓形成能力[0(0 - 4.4)mg;P < 0.01],而对照抗体则无作用[19.6(12.6 - 53.7)mg;P > 0.05]。微颗粒的血栓形成能力与其TF暴露密切相关(r = 0.9524,P = 0.001)。
人细胞衍生的微颗粒以TF依赖的方式促进体内血栓形成。它们可能是各种患者群体中血栓栓塞倾向增加的直接原因。